Qubit Pharmaceuticals: EIC Accelerator Money for Quantum Drug Design

Most drugs are still found by testing huge libraries of molecules in the lab. Computer simulation promises to narrow the search, but the physics of how a drug binds its target is expensive to compute accurately. Qubit Pharmaceuticals, founded in Paris in 2020 by five academics who spent years building molecular simulation software, is betting that faster supercomputing today, and quantum computing tomorrow, can make those calculations cheap enough to design drugs from scratch.

The European Innovation Council paid €2.5 million towards a €4.25 million project to build that platform, called Atlas. The project delivered software, papers, patents and preclinical drug leads. What it did not produce, and could not in two years, is a medicine in clinical trials.

What Qubit Pharmaceuticals Does Today

Qubit runs two businesses in one. The first is drug discovery: the company says it is building a pipeline of up to ten in-house programmes in oncology and inflammation, found with its own simulation platform. The second is quantum computing research, which it pursues through partnerships with the French quantum hardware company Pasqal, with national computing centres and, since April 2026, with Singapore's Centre for Quantum Technologies, to test quantum sampling algorithms on real hardware.

Its most visible quantum result is Hyperion, an emulator developed with Sorbonne University that the company says cuts by a factor of ten the number of qubits needed to simulate molecules. According to the CORDIS report, Hyperion was awarded €8 million from the France 2030 plan.

The Technology: Physics Before Chemistry

The key calculation in structure-based drug design is the binding free energy: how tightly a candidate molecule sticks to its protein target. Doing it accurately means simulating the motion of every atom, including the way electrons shift around each other, which is what polarisable force fields model. Qubit's founders built simulation software for exactly that over what their investor Omnes describes as more than 15 years of academic research. Atlas combines them with GPU supercomputing, machine learning for predicting toxicity, and quantum processors for the parts of the chemistry where classical computers struggle.

The EIC project reports that the cost of an absolute binding free energy calculation fell from €400 to €100 per compound, and that an AI model for absorption and toxicity reached "92% accuracy compared to experimental data". Both figures are the company's own.

What the EIC Project Promised, and What CORDIS Shows

ATLAS ran from 1 September 2022 to 31 August 2024 under the 2021 challenge for Strategic Digital and Health Technologies. Its goal was a "next generation HPC/QC in silico drug discovery platform for de novo design". The closing report lists six drug discovery projects launched in oncology and inflammation, preclinical leads across several chemical series against KAT6A, an oncology target, the integration of quantum processing units into the workflow, and a body of academic and intellectual property output.

1. A hybrid HPC and quantum design platformDeliveredPipeline automation, faster binding calculations and quantum processors integrated, per CORDIS.
2. De novo drug candidatesPartialPreclinical leads against KAT6A; no candidate in clinical development.
3. Intellectual propertyDeliveredEight patents and twelve papers reported.
4. Quantum advantage in drug discoveryNot shownQuantum work remains at the emulator and algorithm stage.

What Has Happened Since

The Money

Qubit raised a €16.1 million seed round in June 2022, bringing its total to €23 million since 2020, from XAnge, Omnes, Quantonation and OVH founder Octave Klaba. It then had 20 staff and planned to reach 60 across Paris and Boston.

The accounts reported by Societe.com, with 2023 matched by Pappers, show small revenues (€76,700 in 2023, €187,300 in 2024) and modest reported losses (€133,400 and €795,900); the public summary does not show how grants or research tax credits enter those figures. The notable change is on the balance sheet: debt rose from €3.7 million to €16.3 million in 2024 while equity fell from €3.5 million to €2.4 million.

Why Europe Should Care

Qubit sits where two EU priorities meet: health technology and quantum computing. The Commission's Quantum Europe Strategy of July 2025 aims to make the EU a global quantum leader by 2030. A Paris company with founders from Sorbonne University, CNRS and the Conservatoire national des arts et métiers, working with French quantum hardware makers and national supercomputers, is the kind of European ecosystem the EIC wants to build.

The Verdict

Qubit Pharmaceuticals has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.